Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Steve D. Thomas"'
Autor:
David I. Stirling, Sandy Morseth, Kevin H. Denny, Steve K. Teo, Alan M. Hoberman, Steve D. Thomas
Publikováno v:
Toxicological Sciences. 81:379-389
The present study determined effects of thalidomide on three successive generations of New Zealand White rabbits after oral dosing to F0 maternal rabbits during the later third of gestation (post major organogenesis) and lactation. One hundred and tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1442595d1050f262f2cedd080a0bacd7
https://doi.org/10.1093/toxsci/kfh207
https://doi.org/10.1093/toxsci/kfh207
Autor:
Steve D. Thomas, Sandra L. Morseth, Kevin H. Denny, Steve K. Teo, David I. Stirling, Alan M. Hoberman
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 71:1-16
BACKGROUND: The present work was performed to determine the effect of thalidomide exposure on reproductive function and early embryonic development. METHODS: Twenty-five female New Zealand White rabbits were orally gavaged with 0, 10, 50, or 100 mg/k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f009c1a0bfe4277d0ac46ec6c8c624c
https://doi.org/10.1002/bdrb.10054
https://doi.org/10.1002/bdrb.10054
Autor:
Karin A. Kook, Markian S. Jaworsky, Steve K. Teo, William Tracewell, Michael A. Scheffler, David I. Stirling, Wayne A. Colburn, Steve D. Thomas, Oscar L. Laskin
Publikováno v:
Clinical Pharmacokinetics. 43:311-327
Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy. In addition, its use in various inflammatory and oncologic conditions is being investigated. Thalidomide interconverts betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4393f2aa140453d0754ee9d1d9c32b99
https://doi.org/10.2165/00003088-200443050-00004
https://doi.org/10.2165/00003088-200443050-00004
Autor:
Vikram Khetani, Alan M. Hoberman, Steve D. Thomas, Steve K. Teo, David I. Stirling, Mildred S. Christian
Publikováno v:
Reproductive Toxicology. 16:353-366
d -Methylphenidate is an enantiomer of d , l -methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder (ADHD) in children. The current study was performed to assess the potential perinatal and postnatal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82ab820a3cae03f4e9533fe7f6f5ccdd
https://doi.org/10.1016/s0890-6238(02)00044-8
https://doi.org/10.1016/s0890-6238(02)00044-8
Autor:
Wayne A. Colburn, Karin A. Kook, Steve K. Teo, Steve D. Thomas, David I. Stirling, Michael R. Scheffler, William Tracewell
Publikováno v:
The Journal of Clinical Pharmacology. 41:662-667
Thalidomide is approved in the United States for treating erythema nodosum leprosum, a complication of leprosy. The present study determined the single-dose oral pharmacokinetics and dose proportionality from 50 to 400 mg of Celgene's commercial Thal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0d44701c13b31341240f8d46ffaccfa
https://doi.org/10.1177/00912700122010555
https://doi.org/10.1177/00912700122010555
Autor:
J. Michael Morgan, David I. Stirling, Mark G. Evans, Mark J. Brockman, Steve D. Thomas, Steve K. Teo, Julie Ehrhart
Publikováno v:
Toxicological Sciences. 59:160-168
Fifty-six adult beagle dogs (28 male, 28 female) were orally administered thalidomide at 43, 200, or 1000 mg/kg/day for 53 weeks. Sixteen (2/sex/dose group) and 32 (4/sex/dose group) dogs were euthanized and necropsied after 26 and 53 weeks of dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e4e4744fa5a9815821a9eb2ddbe0962
https://doi.org/10.1093/toxsci/59.1.160
https://doi.org/10.1093/toxsci/59.1.160
Autor:
M Brockman, D Allen, M Morgan, Mark G. Evans, J Ehrhart, Steve D. Thomas, Steve K. Teo, D Stirling
Publikováno v:
Human & Experimental Toxicology. 19:615-622
Thalidomide (Thalomid®) is approved for use in the US to treat complications from leprosy. Peripheral neuropathy is a dose-limiting adverse event in humans. As part of a nonrodent regulatory toxicology study, Beagle dogs were fed orally via encapsul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99eda452261ad8f7cc3cbd1ab7a6d1c1
https://doi.org/10.1191/096032700673027800
https://doi.org/10.1191/096032700673027800
Autor:
Karin A. Kook, William G. Tracewell, David I. Stirling, Steve D. Thomas, Steve K. Teo, Michael R. Scheffler, Wayne A. Colburn
Publikováno v:
Biopharmaceutics & Drug Disposition. 21:33-40
The effect of food on the oral pharmacokinetics of thalidomide and the relative bioavailability of two oral thalidomide formulations were determined in an open label, single dose, randomized, three-way crossover study. Five male and eight female heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ffcb6becfab82a47683a2902f28d3ea
https://doi.org/10.1002/1099-081x(200001)21:1<33::aid-bdd213>3.0.co
https://doi.org/10.1002/1099-081x(200001)21:1<33::aid-bdd213>3.0.co
Publikováno v:
Journal of Biochemical and Molecular Toxicology. 14:140-147
Previous in vitro studies in rat microsomal preparations suggested that thalidomide is metabolized by the cytochrome P450 system (CYP). In this study, we examined the extent of thalidomide metabolism by preparations of pooled human microsomes, micros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34657a6b4ea60361e6302339ccfed7f9
https://doi.org/10.1002/(sici)1099-0461(2000)14:3<140::aid-jbt3>3.0.co
https://doi.org/10.1002/(sici)1099-0461(2000)14:3<140::aid-jbt3>3.0.co
Publikováno v:
Teratogenesis, Carcinogenesis, and Mutagenesis. 20:301-311
Thalomid® is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a complication of leprosy. The genotoxicity of Thalomid® thalidomide was assessed in the Ames reverse mutation, AS52/XP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d51717942af5b032cbee3e80be1c0b0
https://doi.org/10.1002/1520-6866(2000)20:5<301::aid-tcm6>3.0.co
https://doi.org/10.1002/1520-6866(2000)20:5<301::aid-tcm6>3.0.co